Splenik Marjinal ZonLenfoma: Bir Olgu Sunumu

Öz

Marginal zone lymphomas (MZL) represent a group of low grade lymphomas whose cells originate from B lymphocytes normally present in marginal zone of the secondary lymphoid follicles. According to World Healt Organization (WHO) classifi cation, MZL is described with three subtypes: extranodal MALT lymphoma, splenic MZL and nodal MZL. All threemarginal zone cell lymphomass hareimmuno-phenotypic, genetic and chromosomal similarities. Extranodal MALT lymphoma is an indolent disease that presents within volvement of mucosa associated lenfoid tissue (MALT) by a long-persistent local-ized mass with less frequent bone marrow and peripheral lymphnode involvement. We would like to report a 84 year old woman with splenic marginal zone lymphoma who presented with weak ness and fatigue

Anahtar Kelimeler

• Splenic Marginal Zone Lymphoma,peripheral smear,bone marrow fl owcy tometry

Splenik Marjinal ZonLenfoma: Bir Olgu Sunumu

Öz

Marjinal zonlenfomalar(MZL) sekonderlenfoidfolliküllerinmarjinalzonunda bulunan B lenfositlerden köken alan düşük dereceli lenfomalardır. Dünya Sağlık Örgütü (WHO)'nün sınıfl andırmasına göre marjinalzonlenfomalar, ekstranodal MALT lenfoma, splenikMZL ve nodalMZL olmak üzere 3 alt gruba ayrılır. Her 3 grubun kromozomal, genetik ve immünfenotipik yönden benzerlikleri vardır. Ekstranodal MALT lenfomalar kemik iliği ve periferik lenf nodu tutuluşunun çok nadir görüldüğü, uzun süre lokalize bir kitle olarak kalan, mukoza ile ilişkili lenfoid dokuyu (MALT) tutan yavaş seyirli lenfomalardır. Biz burada halsizlik, yorgunluk şikayeti ile başvuran ve marjinalzonlenfoma tanısı konan 84 yaşındaki bayan olgu sunmayı amaçladık

Anahtar Kelimeler

• Splenik Marginal Zone Lenfoma, periferik yayma, kemik iliği akım sitometrisi

Kaynakça

1. Joshi M, Sheikh H, Abbi K, Long S, Sharma K, Tulchinsky M, Epner E.
2. Marginalzonelymphoma: old, new, targeted, andepigenetictherapies.
3. TherAdvHematol2012;3:275-290.
4. ZinzaniPL. Themanyfaces of marginalzonelymphoma.
5. HematologyAmSocHematolEduc Program 2012;2012:426-432.
6. Arcaini L, Paulli M, Boveri E, Magrini U, Lazzarino M. Marginalzone-related
7. neoplasms of splenicandnodalorigin. Haematologica 2003;88:80-93.
8. Iannitto E, Ambrosetti A, Ammatuna E, Colosio M, Florena AM, Tripodo

9. C, et al. Splenicmarginalzonelymphomawithorwithoutvillouslymphocyt
10. es. Hematologic indingsandoutcomes in a series of 57 patients. Cancer
11. ;101:2050-2057.
12. Parry-Jones N, Matutes E, Gruszka-Westwood AM, SwansburyGJ,
13. WotherspoonAC, Catovsky D. Prognosticfeatures of spleniclymphomawith
14. villouslymphocytes: a report on 129 patients. Br J Haematol 2003;120:759-
15. -
16. Franco V, Florena AM, Iannitto E. Splenicmarginalzonelymphoma. Blood
17. ;101:2464-2472.
18. Thieblemont C, Felman P, Berger F, Dumontet C, Arnaud P, Hequet O, et
19. al. Treatment of splenicmarginalzone B-celllymphoma: an analysis of 81
20. patients. ClinLymphoma 2002;3:41-47.
21. Salido M, Baro C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, et
22. al. Cytogenetic aberrationsandtheirprognosticvalue in a series of 330
23. splenicmarginalzone B-celllymphomas: a multicenterstudy of theSplenic
24. B-Cell LymphomaGroup. Blood 2010;116:1479-1488.
25. Boveri E, Arcaini L, Merli M, Passamonti F, Rizzi S, Vanelli L, et al. Bone
26. marrow histology in marginalzone B-celllymphomas: correlationwithclinic
27. alparameters andflowcytometry in 120 patients. AnnOncol 2009;20:129-
28. -
29. Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, BryonPA,
30. et al. Non- MALT marginalzone B-celllymphomas: a description of
31. clinicalpresentationand outcome in 124 patients. Blood 2000;95:1950-
32. -
33. Kaynaklar